ArticleJournal of gynecologic oncology2024

Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis.

Youwen Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.